Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 12, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
May 09, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25
April 21, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference
April 07, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 24, 2022 08:00 ET
|
Impel NeuroPharma
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study...
Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
March 17, 2022 16:01 ET
|
Impel NeuroPharma
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree
March 17, 2022 08:00 ET
|
Impel NeuroPharma
-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ -$100 million in gross proceeds to be funded at close, extending estimated corporate cash...
Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
February 28, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
January 18, 2022 08:05 ET
|
Impel NeuroPharma
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable...